Revance Therapeutics, Inc.
(NASDAQ : RVNC)

( )
RVNC PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
4.32%20.5514.1%$354.61m
SAGESAGE Therapeutics, Inc.
-2.40%163.3310.9%$242.63m
SHPGShire PLC Sponsored ADR
0.34%148.500.4%$164.05m
MNKMallinckrodt Plc
3.81%23.1518.5%$83.12m
PRGOPerrigo Co. Plc
-0.09%85.526.6%$83.08m
JAZZJazz Pharmaceuticals Plc
0.74%140.002.2%$52.91m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-0.68%122.557.6%$52.70m
UTHRUnited Therapeutics Corporation
-0.44%135.6114.5%$49.94m
ICPTIntercept Pharmaceuticals, Inc.
-0.55%61.3422.0%$38.59m
RVNCRevance Therapeutics, Inc.
3.75%35.9514.1%$38.45m
ENDPEndo International Plc
2.93%7.728.9%$35.88m
ADMSAdamas Pharmaceuticals, Inc.
-2.96%35.4716.9%$34.57m
PCRXPacira Pharmaceuticals, Inc.
-1.34%44.2010.7%$34.22m
PTLAPortola Pharmaceuticals, Inc.
-2.34%51.787.8%$32.70m
MDCOMedicines Company
-0.80%26.0022.1%$32.51m

Company Profile

Revance Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages on the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. It focuses on the development of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.